Stock BJDX BLUEJAY DIAGNOSTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bluejay Diagnostics, Inc.

Equities

BJDX

US0956333019

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
0.547 USD +3.21% Intraday chart for Bluejay Diagnostics, Inc. -14.78% -55.16%
Apr. 02 Bluejay Diagnostics, Inc. Appoints Neil Dey as Principal Financial and Accounting Officer CI
Mar. 28 Bluejay Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 49.92 7.656 1.512
Enterprise Value (EV) 1 30.88 -1.946 -0.3267
P/E ratio -6.25 x -0.82 x -0.13 x
Yield - - -
Capitalization / Revenue - 30,741,459 x -
EV / Revenue - -7,813,548 x -
EV / EBITDA -10 x 0.21 x 0.03 x
EV / FCF -8,604,842 x 352,854 x 60,712 x
FCF Yield -0% 0% 0%
Price to Book 2.53 x 0.67 x 0.52 x
Nbr of stocks (in thousands) 975 1,008 1,239
Reference price 2 51.20 7.598 1.220
Announcement Date 3/10/22 3/20/23 3/28/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales - - - 0.249 -
EBITDA 1 -1.488 -1.039 -3.084 -9.161 -9.663
EBIT 1 -1.631 -1.196 -3.23 -9.318 -10.31
Operating Margin - - - -3,741.48% -
Earnings before Tax (EBT) 1 -0.8198 -1.158 -3.488 -9.297 -9.954
Net income 1 -0.8198 -1.158 -3.488 -9.297 -9.954
Net margin - - - -3,733.11% -
EPS 2 -5.210 -7.361 -8.186 -9.221 -9.078
Free Cash Flow - -0.1367 -3.588 -5.515 -5.381
FCF margin - - - -2,214.38% -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 7/22/21 7/22/21 3/10/22 3/20/23 3/28/24
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q2 2023 Q3 2023 Q4
Net sales 1 - - -
EBITDA - - -
EBIT 1 -2.904 -2.341 -2.387
Operating Margin - - -
Earnings before Tax (EBT) 1 -2.813 -2.298 -2.303
Net income 1 -2.813 -2.298 -2.303
Net margin - - -
EPS 2 -2.750 -2.080 -1.780
Dividend per Share - - -
Announcement Date 8/14/23 11/9/23 3/28/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 0.97 0.14 - - -
Net Cash position 1 - - 19 9.6 1.84
Leverage (Debt/EBITDA) -0.6539 x -0.1381 x - - -
Free Cash Flow - -0.14 -3.59 -5.51 -5.38
ROE (net income / shareholders' equity) - 292% -34.8% -58.2% -138%
ROA (Net income/ Total Assets) - -61.4% -17.9% -33.7% -70.1%
Assets 1 - 1.885 19.47 27.57 14.2
Book Value Per Share 2 -18.60 -26.70 20.30 11.40 2.340
Cash Flow per Share 2 0.6100 5.800 18.90 10.00 1.780
Capex 1 0.01 - 0.02 1.2 0.7
Capex / Sales - - - 481.56% -
Announcement Date 7/22/21 7/22/21 3/10/22 3/20/23 3/28/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

1st Jan change Capi.
BLUEJAY DIAGNOSTICS, INC. Stock Bluejay Diagnostics, Inc.
-55.16% 1.47M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-16.10% 11.41B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+67.65% 3.81B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-14.31% 2.16B
VERACYTE, INC. Stock Veracyte, Inc.
-26.03% 1.56B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+36.95% 1.19B
SEEGENE, INC. Stock Seegene, Inc.
-2.40% 760M
CAREDX, INC Stock CareDx, Inc
-19.00% 506M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-38.57% 444M
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
+13.72% 339M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. BJDX Stock
  4. Financials Bluejay Diagnostics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW